{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:24:43Z","timestamp":1794605083964,"version":"4.9.1"},"reference-count":65,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated with a wide spectrum of immune-related adverse events (irAE) including neurological symptoms which can affect all parts of the central and peripheral nervous system. Even though these events are rare, they are of high relevance as the rate of residual symptoms or even fatal outcomes is remarkable. To provide a detailed overview of neurological adverse events associated with immune checkpoint-inhibitor therapy we conducted a literature search. While focusing on ipilimumab, nivolumab, and pembrolizumab therapy, all available case reports as well as larger case series and clinical trials have been considered. Eighty-two case reports about checkpoint-inhibitor therapy induced symptoms of the peripheral nervous system have been published, while only 43 case reports addressed central nervous system abnormalities. The frequency of immune checkpoint-inhibitor therapy inducing neurological adverse events is about 1% in larger studies. Especially neuromuscular adverse events exhibit distinct clinical and diagnostic characteristics. Additionally, several affected patients presented with overlap-syndromes, which means that symptoms and diagnostic findings indicating myositis, myasthenia gravis, and neuropathy were present in one individual patient at the same time. Thus, neurological and particularly neuromuscular adverse events of immune checkpoint-inhibitor therapy may constitute a new disease entity.<\/jats:p>","DOI":"10.3390\/jcm8111777","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T04:41:27Z","timestamp":1571978487000},"page":"1777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy\u2014Review of the Literature and Future Outlook"],"prefix":"10.3390","volume":"8","author":[{"given":"Nora","family":"M\u00f6hn","sequence":"first","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hannover 30625, Germany"},{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6758-6104","authenticated-orcid":false,"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"},{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"},{"name":"Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover 30625, German"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-7302","authenticated-orcid":false,"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"},{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Satzger","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"},{"name":"Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover 30625, German"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hannover 30625, Germany"},{"name":"Center for Immuno-Oncology (IOZ) Hannover Medical School, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2016-0029","article-title":"Immune checkpoint inhibitors side effects and management","volume":"8","author":"Kourie","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II Study of Ipilimumab for Patients With Metastatic Melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"ref_18","first-page":"58","article-title":"CTLA4 is differentially associated with autoimmune diseases in the Dutch population","volume":"118","author":"Zhernakova","year":"2005","journal-title":"Qual. Life Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/rheumatology\/41.2.180","article-title":"An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies","volume":"41","author":"Vaidya","year":"2002","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/rheumatology\/kev388","article-title":"Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia","volume":"55","author":"Lee","year":"2016","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.humimm.2009.03.016","article-title":"Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases","volume":"70","author":"Balbas","year":"2009","journal-title":"Hum. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"ImmunoTargets Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"857519","DOI":"10.1155\/2013\/857519","article-title":"Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature","volume":"28","author":"Spain","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/CND.0000000000000230","article-title":"Severe Relapse of Vaccine-Induced Guillain-Barr\u00e9 Syndrome After Treatment With Nivolumab","volume":"20","author":"Yuen","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Galmiche, S., Lheure, C., Kramkimel, N., Franck, N., Boitier, F., Dupin, N., Turc, G., Psimaras, D., Aractingi, S., and Gu\u00e9gan, S. (2019). Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: A monocentric retrospective study. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.15756"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mus.26070","article-title":"Neuromuscular complications of immune checkpoint inhibitor therapy","volume":"58","author":"Kolb","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barr\u00e9-like syndrome during pembrolizumab treatment","volume":"58","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy","volume":"375","author":"Saiag","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/mus.25663","article-title":"Facial diplegia after pembrolizumab treatment","volume":"56","author":"Yost","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/CMR.0000000000000598","article-title":"Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma","volume":"29","author":"Gingele","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain\u2013Barr\u00e9 syndrome: Pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Berg","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain\u2013Barr\u00e9 syndrome: A case report","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","article-title":"Peripheral neuropathy associated with ipilimumab: A report of 2 cases","volume":"38","author":"Thaipisuttikul","year":"2015","journal-title":"J. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/ijc.IJC_151_18","article-title":"Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma","volume":"55","author":"Simsek","year":"2018","journal-title":"Indian J. Cancer"},{"key":"ref_50","first-page":"e3371","article-title":"Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy","volume":"10","author":"Manam","year":"2018","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: A case report and a literature review","volume":"387","author":"Joubert","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Ishikawa","year":"2017","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Rapid increase in reporting of fatal immune checkpoint inhibitor associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1212\/NXI.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 Antibody-induced Guillain-Barr\u00e9 Syndrome in a Patient with Metastatic Melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.autrev.2017.04.009","article-title":"Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: Report of four cases and literature review","volume":"16","author":"Santos","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of Immunotherapy for the Practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/11\/1777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:08Z","timestamp":1760189348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/11\/1777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["jcm8111777"],"URL":"https:\/\/doi.org\/10.3390\/jcm8111777","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}